Global Platinum-based Anticancer Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Platinum-based Anticancer Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents used to treat cancer. They are coordination complexes of platinum. These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, popular drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development.
Platinum-based Anticancer Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Platinum-based Anticancer Drugs market is projected to reach US$ 1788.9 million in 2034, increasing from US$ 1541.9 million in 2022, with the CAGR of 2.1% during the period of 2024 to 2034. Demand from Testicular Cancer and Osteosarcoma are the major drivers for the industry.
The classification of platinum based cancer drug includes cisplatin, oxaliplatin, carboplatin and other types. The proportion of oxaliplatin is about 71%.
Platinum based cancer drug is widely used for colorectal cancer, ovarian cancer, lung cancer and other cancer. The most proportion of platinum based cancer drug is for colorectal cancer, and the proportion is about 62%.
Asia-Pacific is the largest market, with a sales market share nearly 53%. Following Asia-Pacific, Europe is the second largest sales place with the sales market share of 17%.
Market competition is intense. Sanofi, Hengrui Medicine, ASK Pharma, Yi Bai Pharmaceutical, Qilu Pharmaceutical and Teva, etc. are the leaders of the industry, with about 42% market shares.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Platinum-based Anticancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sanofi-Aventis
Yakult honsha
Dr Reddy's laboratories
Sun Pharmaceutical
Teva
Fresenius Kabi
Hospira(Pfizer)
Mylan
Taj Pharmaceuticals
Jiangsu Hengrui Medicine
Nanjing Pharmaceutical Factory
Jiangsu Aosaikang Pharmaceutical
Qilu Pharmaceutical
Hisun Pharmaceutical
Luoxin
Lingnan Pharmacy
Hansoh Pharma
Segment by Type
Cisplatin
Carboplatin
Oxaliplatin
Nedaplatin
Others
Testicular Cancer
Osteosarcoma
Breast Cancer
Esophageal Cancer
NSCLC
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Platinum-based Anticancer Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Platinum-based Anticancer Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Platinum-based Anticancer Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Platinum-based Anticancer Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Platinum-based Anticancer Drugs introduction, etc. Platinum-based Anticancer Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Platinum-based Anticancer Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Platinum-based Anticancer Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Platinum-based Anticancer Drugs market is projected to reach US$ 1788.9 million in 2034, increasing from US$ 1541.9 million in 2022, with the CAGR of 2.1% during the period of 2024 to 2034. Demand from Testicular Cancer and Osteosarcoma are the major drivers for the industry.
The classification of platinum based cancer drug includes cisplatin, oxaliplatin, carboplatin and other types. The proportion of oxaliplatin is about 71%.
Platinum based cancer drug is widely used for colorectal cancer, ovarian cancer, lung cancer and other cancer. The most proportion of platinum based cancer drug is for colorectal cancer, and the proportion is about 62%.
Asia-Pacific is the largest market, with a sales market share nearly 53%. Following Asia-Pacific, Europe is the second largest sales place with the sales market share of 17%.
Market competition is intense. Sanofi, Hengrui Medicine, ASK Pharma, Yi Bai Pharmaceutical, Qilu Pharmaceutical and Teva, etc. are the leaders of the industry, with about 42% market shares.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Platinum-based Anticancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sanofi-Aventis
Yakult honsha
Dr Reddy's laboratories
Sun Pharmaceutical
Teva
Fresenius Kabi
Hospira(Pfizer)
Mylan
Taj Pharmaceuticals
Jiangsu Hengrui Medicine
Nanjing Pharmaceutical Factory
Jiangsu Aosaikang Pharmaceutical
Qilu Pharmaceutical
Hisun Pharmaceutical
Luoxin
Lingnan Pharmacy
Hansoh Pharma
Segment by Type
Cisplatin
Carboplatin
Oxaliplatin
Nedaplatin
Others
Segment by Application
Testicular Cancer
Osteosarcoma
Breast Cancer
Esophageal Cancer
NSCLC
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Platinum-based Anticancer Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Platinum-based Anticancer Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Platinum-based Anticancer Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Platinum-based Anticancer Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Platinum-based Anticancer Drugs introduction, etc. Platinum-based Anticancer Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Platinum-based Anticancer Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices